Insights

Why the Anteotech (ASX:ADO) share price is soaring 10% today

The Anteotech (ASX: ADO) share price is soaring today as the company annnounces an important manufacturing contract. We take a closer look.
The post Why the Anteotech (ASX:ADO) share price is soaring 10% today appeared first on The Motley Fool Australia. –

increase in asx medical software share price represented by doctor making excited hands up gesture

Anteotech Ltd (ASX: ADO) shares are shooting upwards today after the company announced it has received an important manufacturing contract. At the time of writing, the Anteotech share price is trading 10% higher at 33 cents. 

Anteotech is an Australian based biotech company that aims to solve global industry problems across a number of segments. In particular, the company operates in the life sciences, diagnostics, energy and medical devices markets.

What’s driving the Anteotech share price?

The Anteotech share price is soaring today after the company released news of an important agreement with Operon. To this point, the biotech has finalised and signed a manufacturing contract for its COVID-19 antigen rapid test (ART), EuGeni, with the Spanish company.

The announcement comes after the successful completion of the technology transfer in March, which also saw the Anteotech share price jump by 15%.

Moreover, under the terms of the agreement, the companies have agreed to an exclusivity period of three years. During the period, Operon has a manufacturing capacity of 8 million complete tests per annum, giving Anteotech the capacity to fulfil the expected demand for EuGeni.

Regulatory compliance

Anteotech is now a legal manufacturer of a medical device which means the company’s quality management system (QMS) needs to be compliant with both domestic and international regulatory authorities. As such, over the next 12 months, Anteotech will submit a range of tests to the TGA, FDA and Europe’s equivalents.

Furthermore, due to the emerging need to enhance its QMS, the company will also bring forward its Eugeni tests by 3 months, while delaying its TGA submission by the same time frame. This will allow findings from the trial to be included in the TGA submission. To this point, the deferral will not hinder the current roll-out and distribution of the ART internationally.

As stated by the company:

In fact, we believe the international markets provide a much stronger opportunity. To date, a high level of enquiries for the ART have been fielded from jurisdictions in which our CE Mark is accepted or where other regulatory approvals or emergency use authorisations are required.

About the Anteotech share price

The Anteotech share price has performed remarkably over the last 12 months. It’s gained an astounding 1,400% as the company saw interest in its products increase during the global pandemic.

The company’s validation-of-saliva samples for its rapid test are currently underway. Pending analysis and results of the saliva samples, Anteotech remains on track to provide an update in June 2021.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Anteotech (ASX:ADO) share price is soaring 10% today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!